东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06887 东阳光药

已收盘 05-06 16:08:10

43.640

-1.980

-4.34%

最高45.600	最低43.360	成交量44.25万
今开45.600	昨收45.620	日振幅4.91%
总市值251.37亿	流通市值48.88亿	总股本5.76亿
成交额1,944万	换手率0.40%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":43.64,"timestamp":1778054890006,"preClose":45.62,"halted":0,"volume":442514,"delay":0,"changeRate":-0.04340201665935987,"floatShares":112000000,"shares":576000000,"eps":0.6328850961124041,"marketStatus":"已收盘","change":-1.98,"latestTime":"05-06 16:08:10","open":45.6,"high":45.6,"low":43.36,"amount":19443702,"amplitude":0.049101,"askPrice":44.06,"askSize":10000,"bidPrice":43.64,"bidSize":2900,"shortable":3,"etf":0,"ttmEps":0.6029668915689086,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":5,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":45.62,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":1.038365,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887","defaultTab":"news","newsList":[{"id":"1181862677","title":"东阳光药公布4月股份变动月报 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1181862677","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181862677?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:12","pubTimestamp":1778058743,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年5月6日发布截至2026年4月30日的证券变动月报表。报告期内，公司注册股本总额保持为人民币576,656,047元，其中H股112,712,832股，内资股463,943,215股，面值均为每股人民币1元。内资股于本月无增减，保持已发行及库存股份数量各463,943,215股和0股不变。公司未披露任何当月新增股份发行、可换股票据、期权授予及股权激励计划的变动。公司总股本于报告期末保持稳定。该公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632813969","title":"东阳光药(06887)：甘精胰岛素注射液获得美国食品药品监督管理局的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2632813969","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632813969?lang=zh_cn&edition=full","pubTime":"2026-05-04 08:27","pubTimestamp":1777854421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，本集团自主研发的甘精胰岛素注射液获得美国食品药品监督管理局签发的批准信。美国市场及订单情况：本集团甘精胰岛素注射液已成功获得FDA批准上市，正推进门冬胰岛素在美国的开发。本次甘精胰岛素注射液获得FDA批准，为其加速拓展全球市场奠定了至关重要的准入基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1191","06887","159151"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123300059","title":"东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123300059","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123300059?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:39","pubTimestamp":1777538398,"startTime":"0","endTime":"0","summary":"东阳光药在2025年度实现收入人民币48.15亿元，较2024年的40.19亿元增长19.81%。公司毛利为36.85亿元，毛利率由上年的76.11%提升至76.54%。归属于公司权益股东的净利润录得2.72亿元，相比2024年亏损2.07亿元，出现大幅扭亏为盈；净利润率由0.62%升至5.61%。经营溢利达6.69亿元，除税前溢利为4.40亿元，各项盈利指标均显著增长。每股基本收益为人民币0.56元，上年同期为每股基本亏损0.47元。公司年内经营活动所得现金净额达11.55亿元，较上年增长130.54%，显示经营现金流量明显改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631597371","title":"东阳光药(06887)：中国证监会就公司H股全流通申请出具备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2631597371","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631597371?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:46","pubTimestamp":1777459565,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月29日，本公司收到中国证监会就本次H股全流通申请出具日期为2026年4月27日《关于广东东阳光药业股份有限公司境内未上市股份“全流通”备案通知书》(备案通知书)。据此，本公司已就本次H股全流通向中国证监会完成备案。根据备案通知书，若本公司自备案通知书出具之日起12个月内未完成本次H股全流通转换及上市，如拟继续推进，应当更新备案材料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药(06887)：中国证监会就公司H股全流通申请出具备案通知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153379507","title":"东阳光药4月28日回购700股股份，总额约2.89万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153379507","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153379507?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:47","pubTimestamp":1777369667,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月28日公告回购700股H股，占当日公司已发行股本约0.0006%。本次回购价格介乎每股41.08港元至41.44港元，总金额28,870港元，约合2.89万港元。回购完成后，公司已发行股份总数仍为112,712,832股，其中112,035,232股为流通股，库藏股增至677,600股。公司确认已遵守香港联合交易所有限公司的相关上市规则及有关法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月28日回购700股股份，总额约2.89万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630374149","title":"东阳光药(06887)4月28日斥资2.89万港元回购700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630374149","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630374149?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:44","pubTimestamp":1777369441,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月28日，该公司斥资2.89万港元回购700股股份，每股回购价41.08-41.44港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115717996","title":"东阳光药4月23日回购1300股股份，总额约5.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115717996","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115717996?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:34","pubTimestamp":1776940496,"startTime":"0","endTime":"0","summary":"东阳光药于2026年4月23日在香港联交所场内回购1300股股份，占公司现有已发行股本约0.0012%。本次回购每股价格介乎港币41.52港元至41.90港元，合计耗资约54,256港元。回购完成后，公司已发行股本变动为112,035,932股，库藏股数为676,900股，已发行股本总数保持112,712,832股。公司购回授权于2025年12月16日获股东大会通过，最多可回购57,665,604股。公司确认，本次回购遵守香港联交所上市规则及相关法例。公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月23日回购1300股股份，总额约5.43万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880347","title":"东阳光药(06887)4月23日斥资5.43万港元回购1300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880347","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880347?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:27","pubTimestamp":1776940059,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月23日该公司斥资5.43万港元回购1300股，回购价格为每股41.52-41.90港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880358","title":"东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880358?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:25","pubTimestamp":1776939928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，于2026年4月17日至22日在美国加利福尼亚州圣地亚哥举行的 2026年美国癌症研究协会年会上，本集团以三份壁报形式集中展示了肿瘤治疗领域三款在研管线的最新临床前研究成果。上述三款创新药物在AACR年会上的集中亮相，不仅丰富了本集团的差异化产品管线，更展现了本集团在攻克不可成药靶点及开发下一代免疫疗法方面的技术积累与战略决心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06978","159992","06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118184902","title":"东阳光药4月21日回购6000股股份，总额约26.35万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118184902","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118184902?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:10","pubTimestamp":1776766259,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月21日公告回购6000股H股普通股份，占当日已发行股本约0.0054%。本次回购价格区间介乎每股43.58港元至44.12港元，涉及总金额约263,504港元。完成回购后，公司已发行股本由原先的112,043,232股降至112,037,232股，库藏股数量由669,600股增至675,600股。截至公告日，公司已累计回购675,600股，剩余额度为56,990,004股。公司同时确认，此次回购事务已遵守香港联交所上市规则及相关法例规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月21日回购6000股股份，总额约26.35万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168981507","title":"东阳光药回购2,000股股份，总额约8.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168981507","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168981507?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:12","pubTimestamp":1776683527,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司（下称“东阳光药”，股票代码：06887）2026年4月20日发布公告，披露最新股份回购进展。\n公告显示，公司于当日通过香港联交所场内回购2,000股H股，占公司已发行股本约0.0018%。回购价格介乎每股44.18港元至44.46港元，涉资总额约8.86万港元。\n回购完成后，公司已发行股本变动至112,043,232股，库藏股数量增至669,600股。根据公告，公司于2025年12月16日获股东大会批准购回授权，可回购股份总数为57,665,604股。\n公司同时确认，相关回购程序已遵守香港联交所上市规则及相关法律规定。本次公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628900742","title":"东阳光药(06887)4月20日斥资8.86万港元回购2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628900742","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628900742?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:07","pubTimestamp":1776683246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月20日斥资8.86万港元回购2000股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153727934","title":"东阳光药：4月17日回购2,500股，耗资约11.13万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153727934","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153727934?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:22","pubTimestamp":1776424959,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月17日公告回购股份。公司当日于香港联交所场内回购2,500股，约占已发行股本的0.0022%。每股回购价介乎港币44.18元至44.66元，总金额为港币111,250元。回购完成后，公司已发行股本总数维持在112,712,832股，其中112,045,232股为公众持股，库藏股为667,600股。公司此前于2025年12月16日获得回购授权，可回购最多57,665,604股。公司确认本次股份回购严格遵守上市规则和相关法规。公告由公司董事张英俊签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628203308","title":"东阳光药(06887)4月17日斥资11.1万港元回购2500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628203308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628203308?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:20","pubTimestamp":1776424842,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月17日斥资11.1万港元回购2500股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627215379","title":"东阳光药(06887)：精蛋白人胰岛素混合注射液(30R)预填充规格获得中国国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2627215379","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627215379?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:01","pubTimestamp":1776344476,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，集团自主研发的精蛋白人胰岛素混合注射液预填充规格正式获得中国国家药品监督管理局的上市批准，此次获批进一步丰富了公司在糖尿病领域药物产品线，也为中国糖尿病患者带来更多，更便捷的胰岛素用药选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158475145","title":"东阳光药预充式笔型混合精蛋白人胰岛素注射液(30R)获中国NMPA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1158475145","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158475145?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:00","pubTimestamp":1776344417,"startTime":"0","endTime":"0","summary":"东阳光药宣布，其研发的预充式笔型混合精蛋白人胰岛素注射液(30R)已正式获得中国国家药品监督管理局的上市批准。\n该产品的获批标志着公司在糖尿病治疗领域取得了重要进展。预充式笔型设计为患者提供了更便捷的给药方式，有望提升用药依从性。\n混合精蛋白人胰岛素注射液(30R)作为经典的胰岛素制剂，在糖尿病管理中具有重要临床价值。此次获批将进一步丰富公司的产品管线，增强市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627285608","title":"东阳光药(06887.HK)4月15日耗资5.3万港元回购1200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285608","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627285608?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:37","pubTimestamp":1776249421,"startTime":"0","endTime":"0","summary":"格隆汇4月15日丨东阳光药(06887.HK)公告，4月15日耗资5.3万港元回购1200股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260415/32145696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138875895","title":"东阳光药：4月15日回购1,200股，耗资约5.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138875895","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138875895?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:18","pubTimestamp":1776248292,"startTime":"0","endTime":"0","summary":"东阳光药(06887)于2026年4月15日公告，宣布在香港联交所场内回购1,200股H股，占公司已发行股本约0.0011%。回购价格介乎每股43.80港元至44.24港元，合计支付约5.30万港元。\n回购完成后，公司已发行股本约为112,047,732股，库存股数量增至665,100股。该次回购依据2025年12月16日通过的购回授权展开，根据授权可回购的总规模为57,665,604股，公司迄今累计已回购665,100股。\n公司确认已遵守香港联交所主板上市规则及相关法例。本次公告由公司董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115094263","title":"东阳光药4月14日回购2,500股股份，涉资约11.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115094263","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115094263?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:33","pubTimestamp":1776162792,"startTime":"0","endTime":"0","summary":"东阳光药于2026年4月14日发布公告，称公司当日在香港联交所场内回购2,500股H股。该回购股份占公司已发行股本约0.0022%，回购价格介乎每股港币43.98元至44.42元，涉资约港币11.06万元。本次回购完成后，公司已发行股本总数仍为112,712,832股，其中非库藏股112,048,932股，库藏股增至663,900股。公司披露，其回购授权于2025年12月16日通过，授权回购股份总数为57,665,604股。公告由董事张英俊签署，公告日期为2026年4月14日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417363","title":"东阳光药(06887)4月14日斥资11.06万港元回购2500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417363","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627417363?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:26","pubTimestamp":1776162414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月14日，该公司斥资11.06万港元回购2500股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1041},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.1176},{"period":"6month","weight":-0.0363},{"period":"1year","weight":-0.2427},{"period":"ytd","weight":0.0004}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0353},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药，亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威（磷酸奥司他韦），用于治疗流行性感冒（特别是甲型及乙型流行性感冒病毒），东卫恩（磷酸依米他韦），用于治疗丙型肝炎，及主要用于治疗敏感细菌引起的感染的仿制药，即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病，包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}